

Effect of Air Disinfection Biosecurity (ADB) Technology Creating a Safer Environment for Control of Human Coronavirus on Various Inoculated Surfaces†

ABSTRACT

Human coronavirus is an enveloped, positive-sense, single-stranded RNA virus which enters its host cell by the ACE2 receptor. Infection with the virus has been confirmed worldwide and has an association with many common symptoms and diseases. Associated diseases include mild to moderate upper respiratory tract infections, severe lower respiratory tract infection, croup and bronchiolitis. The virus originated from infected palm civets and bats. HCoV-NL63 is one of seven known coronaviruses to infect humans, including HCoV-229E, HCoV-OC43, HCoV-HKU1, MERS-CoV, the original SARS-CoV (or SARS-CoV-1) and SARS-CoV-2.

The novel human coronavirus SARS-CoV-2 has become a global health concern causing severe respiratory tract infections in humans. Human-to-human transmissions have been described, probably via droplets but possibly also via contaminated hand or surfaces. In a recent review on the persistence of human and veterinary coronaviruses on inanimate surfaces it was shown that human coronaviruses such as Severe Acute Respiratory Syndrome (SARS) coronavirus, Middle East Respiratory Syndrome (MERS) coronavirus or endemic human coronavirus (HCoV) can persist on inanimate surfaces like metal, glass or plastic for up to 9 days.

The virus that causes coronavirus disease 2019 (COVID-19) is stable for several hours to days in aerosols and on surfaces, according to an earlier study from National Institutes of Health, CDC, UCLA and Princeton University scientists in The New England Journal of Medicine. The scientists found that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was detectable in aerosols for up to three hours, up to four hours on copper, up to 24 hours on cardboard and up to two to three days on plastic and stainless steel. The results provide key information about the stability of SARS-CoV-2, which causes COVID-19 disease, and suggests that people may acquire the virus through the air and after touching contaminated objects.

This study will analyze the effects of ADB Technology technology against Human Coronavirus HCoV at 24°C (75°F) and a relative humidity (RH) 40% and treatment time of 15, 30-minutes, 1, 2, 4, 8, 12 and 24-hours. A selection of surfaces have been studied using response surface methodology (RSM). In these tests the log reduction of the above-mentioned problematic virus demonstrates the inactivation effects delivered with the ADB Technology treatment. The statistical analysis of developed predictive model suggested that concentration, RH and treatment time all significantly ($P < 0.01$) increased the rate of log reduction. Among the three (3) factors, the effect of treatment concentration on inactivation was the greatest, while effect of RH was the least. The interaction between concentration and RH exhibited a

† Mention of trade names or commercial products does not imply recommendation or endorsement to the exclusion of other products.

A. Current Trail

This trial was designed to demonstrate the benefits of using the ADB Technology technology to reduce/preclude this specific virus on various surfaces: plastic, stainless steel, and floor tile coupons (used in commercial/hospitals).

For this trial Human Coronavirus NL63 HCoV (ATCC # VR-3263SD) was studied.

Previously, the ADB technology has been demonstrated to have beneficial effects on the reduction of bacteria, mold and food pathogens in refrigerated and non-refrigerated environments. In a growing number of commercial applications, these benefits have enabled perishable product processors, growers/shippers, wholesalers and retailers of perishable commodities to significantly expand their marketing window, reduce losses due to decay and disease and reduce operational risk and costs.

B. Materials and Methods

Viral culture

Human Coronavirus NL63 HCoV (ATCC # VR-3263SD), was acquired from ATCC, Manassas, VA., USA. and maintained on ATCC complete growth medium and minimum essential medium (ATCC, Manassas, VA., USA) with 2 μ M L - glutamine and Earle's BSS adjusted to contain 1.5 g/L sodium bicarbonate, 0.1 μ M non-essential amino acids, and 1.0 μ M sodium pyruvate, 90%; fetal bovine serum, 10% and cultured in Trypticase Soy Agar with added; sodium bicarbonate, non-essential amino acids, and combination of sodium pyruvate and fetal bovine serum, in aerobic growth conditions at 33-35°C.¹

Cells from both of the above (approx. 1×10^7 CFU/ml) from a 24-hour static culture incubated at 33-35°C were used to inoculate various 5 cm x 5 cm plastic, stainless steel, and floor tile coupons.

The inoculum suspensions were enumerated by surface plating in duplicate samples on TSA after serial dilution in 0.1% peptone solution. The plates were incubated for 24- hours at 37°C.

C. Inoculation of various media surface areas

A 100 μ l droplet from the initial inoculum suspension of the virus culture was used to inoculate the external surface (5 cm x 5 cm) on plastic, stainless steel and floor tile coupons, with the final inoculum level to be approximately 7.5-log_{10} CFU/g sample. The inoculated samples were dried by air-blowing for 1-hour at 22°C prior to the treatment being initiated. The 1-hour drying allows the inoculated cells to attach to the surface host and minimize the growth of inoculated cells during drying.

D. Treatment

Treatment was carried out using an ADB Technology 4007 unit installed in a testing chamber. The chamber was monitored by the built-in smart controller and gas sensors to monitor H₂O₂ and O₃ (indicators of reactive oxygen species production) as well as temperature and relative humidity.

The plastic, stainless steel and floor tile (5 cm x 5 cm) coupon surfaces were inoculated with the virus and were treated with a setpoint of 0.10 ppm H₂O₂ (calculated) and 0.04 ppm O₃ concentration for 15, 30-minutes, 1, 2, 4, 8, 12 and 24-hour increments at 24°C (75°F) at 40% RH. After the treatment, the samples were subjected to enumeration by surface plating. The log reduction of the virus was evaluated with and without the consideration of resuscitation of injured cells after treatment.

¹ Cells expressing heteroresistance grow more slowly than the oxacillin-susceptible population and may be missed at temperatures above 35°C. This is why CLSI recommends incubating isolates being tested against oxacillin, methicillin, or nafcillin at 33-35° C (maximum of 35°C) for a full 24 hours before reading.

Three different controls were prepared in each treatment. For a positive control, a 5 cm x 5 cm area of the three coupons were inoculated with virus cells and dried for 1- hour but not exposed to the treatment. There were three negative controls, in which the 5 cm x 5 cm coupons were inoculated with 100 µl droplet of sterile water and dried for 1 hour.

One negative control was treated with ADB Technology and the other was not subjected to the treatment. Each treatment sample and the 3 controls were prepared in triplicate.

E. Recovery of pathogens from the surface samples

After the treatment, each of the 5 cm x 5 cm coupons were transferred into a 400 ml stomacher bag (Fisher Scientific Inc., PA., USA) combined with 50 ml sterile 0.1%peptone solution, and then blended with a AES Easy Mix Stomacher (AES Laboratories, Princeton, NJ., USA) for 2-min at normal speed. Wash fluid was serially diluted, followed by surface plating for enumeration.

A centrifugation method was used to recover low populations of injured virus. The centrifugation method (Mossel and others 1991) was modified and used to concentrate the virus populations in the wash fluid so that less than 250 CFU/ml of bacteria can be enumerated by the surface plating.

F. Study Results and Discussion Following

Treatment with the ADB Technology unit, the average reductions of the Human Coronavirus was 4.21-log10 in plastic, 4.32-log10 in stainless steel and 4.22-log10 in floor tile following 15-minute treatments, based on the infectious virus recovery. Following treatment times of 30- minutes, 1, 2, 4, 8, 12 and 24-hours on the inactivation of the virus on a selection of surface samples is noticeable from the Table attached.

1. Overall log reduction

- The 15-minute treatment results show a slightly greater average reduction on Human Coronavirus at 4.32-log10.
- The 30-minute treatment results again shows a greater average reduction on Human Coronavirus at 6.63-log10.

2. Impact on the organism

- The largest reduction 4.32-log10 was seen after the first 15-minute exposure on stainless steel. A 99.99% decrease.
- The second largest reduction 6.63-log10 was seen after 30-minute exposure on stainless steel. A 99.9999% decline.

3. Impact on surfaces

- After 30-minute exposure the stainless-steel coupons showed the greatest reduction of 6.63-log10 followed by the plastic and the floor tile coupons at 6.52-log10 and 6.48-log10, respectively.


G. Conclusion

This study shows the significant effect of the ADB Technology treatment in reducing HCoV viral cultures on surfaces. The process carried out by this technology inactivates viruses by breaking the protein envelope and inactivating the RNA strand. The results are unambiguous and indicate a clear correlation between ADB Technology treatment at the indicated concentrations and the stated log reductions of the virus on all surfaces tested.

TABLE 1. Human Coronavirus NL63 populations following treatment with Air Disinfection Biosecurity (ADB) system.

Time	Plastic			Stainless Steel			Floor Tile		
	Log ₁₀ Variance	Standard Deviation	Reduction	Log ₁₀ Variance	Standard Deviation	Reduction	Log ₁₀ Variance	Standard Deviation	Reduction
0	7.48	0.4	-	7.48	0.3	-	7.48	0.2	-
15-m	3.27	0.2	4.21	3.16	0.3	4.32	3.26	0.3	4.22
30-m	<1	0.1	6.48	0.85	0.2	6.63	0.95	0.2	6.52
1-h	<1	0.1	7.48	<1	0.1	7.48	<1	0.1	7.48
2-h	<1	0.1	7.48	<1	0.1	7.48	<1	0.1	7.48
4-h	<1	0.1	7.48	<1	0.1	7.48	<1	0.1	7.48
8-h	<1	0.1	7.48	<1	0.1	7.48	<1	0.1	7.48
12-h	<1	0.1	7.48	<1	0.1	7.48	<1	0.1	7.48
24-h	<1	0.1	7.48	<1	0.1	7.48	<1	0.1	7.48

GRAPHIC REPRESENTATION OF RESULTS



REFERENCES

1. WHO Novel Coronavirus (2019-nCoV). Situation Report 12. Who; 2020 Büchen-Osmond, C (Ed), Columbia University, New York, USA.
2. Index of Viruses - Orthomyxoviridae (2006). In: ICTVdB - The Universal Virus Database, version 4". Columbia University, New York, USA. 2006.
3. Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronavirus on inanimate surfaces and its inactivation with biocidal agents. *J Hosp Infect* 2020. <https://doi.org/10.1016/j.jhin.2020.01.022>
4. Kampf G. Potential role of inanimate surfaces for the spread of coronaviruses and their inactivation with disinfectant agents. *Healthcare Infection Society* 2020. <https://doi.org/10.1016/j.jinfpip.2020.100044>
5. Jones LD, Nuttall PA (1989). "Non-viraemic transmission of Thogoto virus: influence of time and distance". *Trans. R. Soc. Trop. Med. Hyg.* 83 (5): 712–4.
6. WHO. 2006. Nonpharmaceutical Interventions for Pandemic Influenza, International
7. Lim, Yvonne Xinyi; Ng, Yan Ling; Tam, James P.; Liu, Ding Xiang (2016-07-25). "Human Coronaviruses: A Review of Virus–Host Interactions". *Diseases*
8. Measures. *Emerging Infectious Disease* 12:81-87. Hay A, Gregory V, Douglas A, Lin Y (Dec 29 2001). "The evolution of human influenza viruses" (PDF). *Philos Trans R Soc Lond B Biol Sci* 356 (1416): 1861–70.
9. Reed, L. J. and H. Muench. 1932. A simple method for estimating 50% endpoints. *American Journal of Hygiene* 27:493-497
10. Avian Influenza (Bird Flu)". Centers for Disease Control and Prevention.8. Atkinson W, Hamborsky J, McIntyre L, Wolfe S,(2007). *Epidemiology and Prevention of Vaccine-Preventable Diseases* (10th ed.). Washington DC: Centers for Disease Control and Prevention.
11. Avian Influenza (Bird Flu): Implications for Human Disease". Center for Infectious Disease Research & Policy, University of Minnesota. 2007-06-27.
12. Fouchier R, Schneeberger P, Rozendaal F, Brockman J, Kemink S, Munster V, Kuiken T, Rimmelzwaan G, Schutten M, Van Doornum G, Koch G, Bosman A, Koopmans M, Osterhaus A (2004). "Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome". *Proc Natl Acad Sci USA* 101 (5): 1356–61.
13. Hilleman M (Aug 19, 2002). "Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control". *Vaccine* 20 (25-26): 3068–87.
14. Osterhaus A, Rimmelzwaan G, Martina B, Bestebroer T, Fouchier R (2000). "Influenza B virus in seals". *Science* 288 (5468): 1051–3.
15. Nobusawa E, Sato K (April 2006). "Comparison of the mutation rates of human influenza A and B viruses". *J Virol* 80 (7): 3675–8.
16. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y (March 1992). "Evolution and ecology of influenza A viruses". *Microbiol. Rev.* 56 (1): 152–79.
17. Zambon M (November 1999). "Epidemiology pathogenesis of influenza". *J Antimicrob Chemother* 44 (Suppl B): 3–9.
18. Matsuzaki Y, Sugawara K, Mizuta K, Tsuchiya E, Muraki Y, Hongo S, Suzuki H, Nakamura K (2002). "Antigenic and genetic characterization of influenza C viruses which caused two outbreaks in Yamagata City, Japan, in 1996 and 1998". *J Clin Microbiol* 40 (2): 422–9.